Sunil et al. performed a meta-analysis that ultimately included five studies and abstracts dealing with autologous SCT for patients with HIV related lymphoma. They were 35 patients with Hodgkin lymphoma and 83 with NHL. Outcomes were as impressive as would be anticipated in a similar non-HIV infected population. After transplant, 71% of patients (95%CI 60-80) achieved complete remission (CR) and 2 year overall survival was 71% (95%CI 61-79). A CR before transplant was highly predictive of a CR after transplant in 2 year overall survival. Overall this meta-analysis confirms the There are caveats to this report as there are in any meta-analysis. This is a retrospective analysis combining results of several case series. In addition there is likely to be significant reporting bias in this field. However the review of five studies including 111 patients support the conclusion that autologous transplant should be offered to HIV-infected patients as clinically appropriate and is not contraindicated. The authors appropriately conclude that prospective trials are necessary (and these data confirm that they are appropriate) and the community should anxiously await results from a planned multicenter prospective trial of autologous SCT in HIV-related lymphoma patients in development by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).